Literature DB >> 22595396

The uncertainty of rituximab and steroid dosing in refractory steroid-resistant nephrotic syndrome.

Daishi Hirano, Shuichiro Fujinaga, Naoto Nishizaki.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22595396     DOI： 10.5414/cn107336

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN： 0301-0430            Impact factor:   0.975


× No keyword cloud information.
  4 in total

Review 1.  Rituximab therapy for refractory steroid-resistant nephrotic syndrome in children.

Authors:  Koichi Kamei; Kenji Ishikura; Mayumi Sako; Shuichi Ito; Kandai Nozu; Kazumoto Iijima
Journal:  Pediatr Nephrol       Date:  2018-12-18       Impact factor: 3.714

2.  Re-treatment with high-dose prednisolone after rituximab infusion for childhood-onset steroid-resistant nephrotic syndrome.

Authors:  Shuichiro Fujinaga; Taichi Hara
Journal:  Pediatr Nephrol       Date:  2014-03-16       Impact factor: 3.714

3.  Long-term outcomes after early treatment with rituximab for Japanese children with cyclosporine- and steroid-resistant nephrotic syndrome.

Authors:  Shuichiro Fujinaga; Tomohiko Nishino; Chisato Umeda; Yuji Tomii; Yoshitaka Watanabe; Koji Sakuraya
Journal:  Pediatr Nephrol       Date:  2018-11-13       Impact factor: 3.714

4.  Rituximab treatment combined with methylprednisolone pulse therapy and immunosuppressants for childhood steroid-resistant nephrotic syndrome.

Authors:  Koichi Kamei; Mari Okada; Mai Sato; Takuya Fujimaru; Masao Ogura; Makiko Nakayama; Hiroshi Kaito; Kazumoto Iijima; Shuichi Ito
Journal:  Pediatr Nephrol       Date:  2014-02-06       Impact factor: 3.651
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.